Command Palette
Search for a command to run...
Circulating Cell-Free Chromatin Particles Trigger a Unique Biphasic STING Signaling Program that Drives DNA Damage and Inflammation
Shabrish, S.; Patade, S.; Shinde, S.; Yelukar, R.; Raghuram, G. V.; Lopes, R.; Khare, N. K.; Mittra, I.
Circulating cell-free chromatin particles are internalised by peripheral blood mononuclear cells and trigger a biphasic STING signalling program, with an early trafficking and IRF3 or NF-kappaB phase preceding DNA damage and a later phosphorylation and cytokine phase; pharmacological inhibition or genetic deletion of STING attenuates both.
Mild contradiction
1 prior failureOne documented clinical failure (Phase 1 or 2) overlaps with the claimed mechanism.
Abstract excerpt
Cell death, DNA damage, and inflammation are closely interconnected processes implicated in ageing, cancer, and inflammatory disorders, yet the endogenous mechanisms linking them remain unclear. We previously identified cell-free chromatin particles (cfChPs), released from dying cells, as biologically active entities that enter neighboring cells and induce DNA damage and inflammation. Here, we show that serum-derived circulating cfChPs are rapidly internalized by human peripheral blood mononuclear cells and trigger a previously unrecognized biphasic STING signaling response. An early phase involves rapid STING trafficking to the perinuclear region and nucleus, with activation of IRF3 and NF-{kappa}B preceding detectable DNA damage. This is followed by a later phase characterized by STING phosphorylation, puncta formation, persistent DNA damage, and robust inflammatory cytokine production. Pharmacological inhibition or genetic deletion of STING markedly attenuated these responses. These findings identify extracellular cfChPs as endogenous DNA-damaging agents and reveal biphasic STING signaling as a mechanistic link between cell death, DNA damage, and sterile inflammation.
Matching Claidex post-mortems
1 of 1 indexedThis is an automated contradiction flag, not an editorial judgment on the preprint's quality. Flags identify where the preclinical literature and the clinical failure record diverge.

